- Home
- NAGE
as 05-30-2025 4:00pm EST
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 861.0M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $11.16 | Next Earning Date: | 05-07-2025 |
| Revenue: | $107,925,000 | Revenue Growth: | 29.77% |
| Revenue Growth (this year): | 25.46% | Revenue Growth (next year): | 21.72% |
Latest Niagen Bioscience Inc. Common Stock News
NAGE Breaking Stock News: Dive into NAGE Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
3 Stocks That May Be Trading Below Their Estimated Value
Simply Wall St.
17 days ago
Exploring May 2025's Undervalued Small Caps With Insider Action
Simply Wall St.
22 days ago
Niagen Bioscience First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
24 days ago
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Business Wire
25 days ago
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
Business Wire
a month ago
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
Simply Wall St.
a month ago
Three High Growth Companies Insiders Are Eager To Hold
Business Wire
a month ago
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
Compare NAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAGE Niagen Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.